- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:00 | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Medicus Pharma GAAP EPS of -$0.21 | 5 | Seeking Alpha | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.08. | Medicus Pharma Ltd: Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 607 | ACCESS Newswire | Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect and Teverelix Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion... ► Artikel lesen | |
| 12.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 03.08. | Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev | 2 | Investing.com | ||
| 03.08. | Medicus Pharma Ltd: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom | 348 | GlobeNewswire (Europe) | PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 31.07. | Medicus Pharma receives UAE approval for endometriosis study | 1 | Investing.com | ||
| 31.07. | Medicus Pharma Ltd: Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix in Women with Endometriosis | 3 | GlobeNewswire (USA) | ||
| 31.07. | EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi | 1 | Benzinga.com | ||
| 27.07. | FDA clears Medicus Pharma Gorlin Syndrome study to proceed | 5 | Investing.com | ||
| 27.07. | FDA gibt grünes Licht für Studie von Medicus Pharma zum Gorlin-Syndrom | 9 | Investing.com Deutsch | ||
| 27.07. | Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Letter for NDA-Enabling Registrational SkinJect Study in Patients with Gorlin Syndrome | 374 | GlobeNewswire (Europe) | PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 25.07. | New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings | 1.131 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / July 25, 2026 / New to The Street, one of America's longest-running sponsored business television brands, today announced the broadcast of its latest episode, airing... ► Artikel lesen | |
| 16.07. | Medicus Pharma Ltd: Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention | 265 | GlobeNewswire (Europe) | PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 04.07. | New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell's Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group | 4.693 | ACCESS Newswire | Honoring Economic Freedom and American Capitalism Through Television That Connects Markets, Entrepreneurs, and InvestorsNational Sponsored Broadcast Includes Executive Interviews and Television Commercial... ► Artikel lesen | |
| 22.06. | Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026 | 9 | Benzinga.com | ||
| 22.06. | Medicus Pharma Ltd: Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 | 7 | GlobeNewswire (USA) | ||
| 15.06. | Medicus Pharma Ltd: Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome | 7 | GlobeNewswire (USA) | ||
| 11.06. | Medicus Pharma submits IND application for endometriosis trial | 3 | Investing.com | ||
| 11.06. | Medicus Pharma Ltd: Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program | 277 | GlobeNewswire (Europe) | PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,690 | -1,40 % | Gewinner der Börsengeschichte: Kaum ein Deutscher kennt diese Heißzeit-Aktie - Sie brachte +3.923.693% Rendite! | © Foto: Christoph Hardt/Geisler-Fotopress - Geisler-FotopressDer US-amerikanische Anbieter von Klimalösungen Trane Technologies gilt als Profiteur des Klimawandels. Die Buy-and-Hold-Gesamtrendite liegt... ► Artikel lesen | |
| GILEAD SCIENCES | 129,08 | -0,05 % | AWSX der Telegram-Trader.de: Gilead: Neue HIV-Zulassung trifft auf starkes Kerngeschäft | ||
| ELI LILLY | 994,70 | -0,61 % | Compass Pathways und Definium nähern sich dem Markt: Warum der nächste Engpass bei Psychedelika Emyria in den Fokus rückt | ||
| VERTEX PHARMACEUTICALS | 482,05 | +0,32 % | Vertex Pharmaceuticals Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team | Crinetics acquisition completed September 1, 2026
Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately
As... ► Artikel lesen | |
| INNOCAN PHARMA | 1,480 | -0,34 % | Innocan Pharma Corporation: Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M) | Second Quarter 2026 Results: Gross Margin of 90.9% and Category Leadership HERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB:... ► Artikel lesen | |
| EYEPOINT | 4,180 | +0,97 % | EyePoint drops as TD Cowen becomes latest to downgrade on late-stage trial setback | ||
| LIGAND PHARMACEUTICALS | 248,00 | 0,00 % | If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today | ||
| JAZZ PHARMACEUTICALS | 213,20 | +0,61 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:Wells... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 7,150 | -2,72 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| UNITED THERAPEUTICS | 416,80 | -1,84 % | United Therapeutics bid to expand nebulized Tyvaso label gets FDA review | ||
| OPKO HEALTH | 1,450 | -1,36 % | OPKO HEALTH, INC. - 10-Q/A, Quarterly Report | ||
| JAGUAR HEALTH | 0,710 | -3,49 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
28.08.2026 / 14:44 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ROYALTY PHARMA | 55,03 | +1,03 % | Biotech Stocks At 52-Week Highs - MiniMed Group +10%, Pulse Biosciences, Solventum, Royalty Pharma, Apogee Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 1, 2026, as various companies reported financial results and reached certain regulatory milestones.MiniMed... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 65,79 | -0,39 % | BridgeBio Pharma, Inc.: Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM | - Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,183 Euro und damit -29,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.